In Vitro Data of Current Therapies for SARS-CoV-2

Author(s): Ioanna A. Anastasiou, Ioanna Eleftheriadou, Anastasios Tentolouris, Dimitrios Tsilingiris, Nikolaos Tentolouris*

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 27 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Background: In December 2019, a new coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged from China, causing pneumonia outbreaks first in the Wuhan region and then spread worldwide. Due to a lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the most efficient tool to find a therapeutic solution.

Objectives: The aim of this study was to summarize in vitro data of current agents used for the management of SARS-CoV-2 all over the world.

Methods: A literature search of articles from January 2000 until April 2020 was performed using MEDLINE, EMBASE and the Cochrane Library to assess in vitro data of current or putative therapies for SARS-CoV-2.

Results: Although in vitro studies are scarce, data regarding chloroquine, hydroxychloroquine, remdesivir, nitazoxanide, teicoplanin, ivermectin, lopinavir, homoharringtonine, and emetine seem promising.

Conclusion: Scientists all over the world should work together and increase their efforts in order to find feasible and efficient solutions against this new global viral threat.

Keywords: SARS-CoV-2 (COVID-19), in vitro studies, VeroE6 Cells, therapies, vaccines, ACE2 receptor.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 27
Year: 2020
Page: [4542 - 4548]
Pages: 7
DOI: 10.2174/0929867327666200513075430
Price: $65

Article Metrics

PDF: 54